QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:DBTX

Decibel Therapeutics - DBTX Stock Forecast, Price & News

$3.54
+0.29 (+8.92%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.25
▼
$3.57
50-Day Range
$1.86
▼
$3.34
52-Week Range
$1.61
▼
$5.78
Volume
469,966 shs
Average Volume
126,307 shs
Market Capitalization
$88.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75

Decibel Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.9% Upside
$11.75 Price Target
Short Interest
Bearish
15.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.11) to ($1.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

526th out of 1,027 stocks

Pharmaceutical Preparations Industry

254th out of 500 stocks

See Top Rated MarketRank™ Stocks Here
DBTX stock logo

About Decibel Therapeutics (NASDAQ:DBTX) Stock

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Receive DBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DBTX Stock News Headlines

January 27, 2023 | americanbankingnews.com
Brokers Set Expectations for Decibel Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:DBTX)
January 24, 2023 | msn.com
Decibel, Regeneron get UK regulator nod to start trial of hearing loss gene therapy
February 6, 2023 | Investing Trends (Ad)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
January 24, 2023 | finance.yahoo.com
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
January 20, 2023 | finance.yahoo.com
Will Decibel Therapeutics (NASDAQ:DBTX) Spend Its Cash Wisely?
January 11, 2023 | msn.com
Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 14, 2022 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Decibel Therapeutics (DBTX)
November 10, 2022 | finanznachrichten.de
Decibel Therapeutics, Inc.: Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
February 6, 2023 | Investing Trends (Ad)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
November 9, 2022 | finance.yahoo.com
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
November 2, 2022 | finance.yahoo.com
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
October 18, 2022 | seekingalpha.com
Decibel Therapeutics hears it may be a takeout target after Lilly acquisition of Akouos
October 17, 2022 | finance.yahoo.com
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
October 14, 2022 | usatoday.com
Save $100 on Bose noise-canceling headphones during the Amazon Prime Early Access sale
October 12, 2022 | finance.yahoo.com
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
September 20, 2022 | finance.yahoo.com
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
August 30, 2022 | nasdaq.com
We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully
August 16, 2022 | seekingalpha.com
Decibel Therapeutics (DBTX) Investor Presentation - Slideshow
August 13, 2022 | finance.yahoo.com
Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation
August 10, 2022 | finance.yahoo.com
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
July 1, 2022 | finance.yahoo.com
Could The Decibel Therapeutics, Inc. (NASDAQ:DBTX) Ownership Structure Tell Us Something Useful?
June 30, 2022 | marketwatch.com
Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX
June 28, 2022 | marketwatch.com
Decibel Therapeutics Shares Rise Premarket on Positive Study Update >DBTX
June 28, 2022 | markets.businessinsider.com
Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study
June 28, 2022 | seekingalpha.com
Decibel Therapeutics up 19% following data on hearing loss drug in cancer patients
June 28, 2022 | finance.yahoo.com
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
June 3, 2022 | finance.yahoo.com
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
See More Headlines
Receive DBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DBTX Company Calendar

Last Earnings
11/09/2022
Today
2/06/2023
Next Earnings (Estimated)
3/17/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBTX
CUSIP
N/A
CIK
1656536
Web
decibeltx.com
Phone
617-370-8701
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.75
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+231.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-51,820,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-50.13%
Return on Assets
-36.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.40
Quick Ratio
5.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.68 per share
Price / Book
0.62

Miscellaneous

Outstanding Shares
24,970,000
Free Float
15,154,000
Market Cap
$88.39 million
Optionable
Not Optionable
Beta
0.14

Key Executives

  • Dr. Laurence E. Reid Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $801.23k
  • Mr. John J. Lee (Age 54)
    Chief Devel. Officer
    Comp: $816.11k
  • Mr. M. Charles Liberman
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Gabriel Corfas
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Ulrich Müller
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Albert S. B. Edge (Age 67)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. James B. Murphy (Age 65)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Ms. Elaine Cope
    VP of Operations
  • Ms. Anna Trask M.A.Ms. Anna Trask M.A. (Age 64)
    Exec. VP & Chief People Officer
  • Mr. Joe Burns Ph.D.
    Sr. VP of Discovery

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













DBTX Stock - Frequently Asked Questions

Should I buy or sell Decibel Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DBTX shares.
View DBTX analyst ratings or view top-rated stocks.

What is Decibel Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued twelve-month price objectives for Decibel Therapeutics' stock. Their DBTX share price forecasts range from $7.00 to $23.00. On average, they expect the company's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 231.9% from the stock's current price.
View analysts price targets for DBTX or view top-rated stocks among Wall Street analysts.

How have DBTX shares performed in 2023?

Decibel Therapeutics' stock was trading at $2.05 on January 1st, 2023. Since then, DBTX shares have increased by 72.7% and is now trading at $3.54.
View the best growth stocks for 2023 here.

When is Decibel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023.
View our DBTX earnings forecast.

How were Decibel Therapeutics' earnings last quarter?

Decibel Therapeutics, Inc. (NASDAQ:DBTX) issued its earnings results on Wednesday, November, 9th. The company reported ($0.64) EPS for the quarter, hitting analysts' consensus estimates of ($0.64).

When did Decibel Therapeutics IPO?

(DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO.

What is Decibel Therapeutics' stock symbol?

Decibel Therapeutics trades on the NASDAQ under the ticker symbol "DBTX."

Who are Decibel Therapeutics' major shareholders?

Decibel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anna Trask, Casdin Partners Master Fund, L, Laurence Reid and Plc Glaxosmithkline.
View institutional ownership trends.

How do I buy shares of Decibel Therapeutics?

Shares of DBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Decibel Therapeutics' stock price today?

One share of DBTX stock can currently be purchased for approximately $3.54.

How much money does Decibel Therapeutics make?

Decibel Therapeutics (NASDAQ:DBTX) has a market capitalization of $88.39 million. The company earns $-51,820,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

How can I contact Decibel Therapeutics?

Decibel Therapeutics' mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The official website for the company is decibeltx.com. The company can be reached via phone at 617-370-8701 or via email at ir@decibeltx.com.

This page (NASDAQ:DBTX) was last updated on 2/6/2023 by MarketBeat.com Staff